GlassScriptPhysician profile
Maria E Rosselson
NPI 1871615419
$8,075.85
in general payments reported to CMS, 2019-2025
35 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $1,201 · 2021: $675 · 2022: $1,035 · 2023: $1,271 · 2024: $663 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Consulting Fee: $750 · Education: $97.99 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.24 |
| Consulting Fee | $750.00 |
| Education | $97.99 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,708.00 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Centurion |
| Rxsight INC | $1,223.58 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $829.03 | 2019-2025 | Dextenza |
| Glaukos Corporation | $577.66 | 2023-2025 | Idosetr, Istent Infinite, Kxl System (Not Refurbished) |
| Abbvie INC. | $462.19 | 2022-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $391.73 | 2022-2025 | Acthar |
| Notal Vision, INC. | $318.90 | 2022 | |
| Sight Sciences, INC. | $280.43 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $268.97 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $246.47 | 2020-2023 | |
| New World Medical,INC. | $204.54 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Sun Pharmaceutical Industries INC. | $202.45 | 2019-2022 | |
| Harrow Eye, LLC | $184.42 | 2024-2025 | Vevye |
| Amgen INC. | $158.85 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $131.38 | 2019-2023 | Tobradex St |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $127.64 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $110.07 | 2022-2024 | Vyzulta, Lotemax Sm, Prolensa |
| Johnson & Johnson Surgical Vision, INC. | $94.86 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Oyster Point Pharma, INC. | $59.51 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $56.02 | 2024-2025 | Xdemvy |
| Beaver-Visitec International, INC. | $49.33 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.86 | 2020 | |
| Thea Pharma INC. | $43.84 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $42.00 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $40.62 | 2024 | |
| Akorn Operating Company LLC | $37.98 | 2021 | |
| Aerie Pharmaceuticals, INC. | $36.58 | 2020-2021 | |
| Ivantis, INC | $26.80 | 2020 | |
| Shire North American Group INC | $24.43 | 2019 | |
| Horizon Therapeutics Plc | $23.29 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.14 | 2022 | |
| Lensar, INC. | $17.12 | 2023 | Lensar Laser System |
| Merck Sharp & Dohme LLC | $12.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Rosselson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.